Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).
Basile D, Broudin C, Emile JF, Falcoz A, Pagès F, Mineur L, Bennouna J, Louvet C, Artru P, Fratte S, Ghiringhelli F, André T, Derangère V, Vernerey D, Taieb J, Svrcek M; for PRODIGE investigators, GERCOR, Fédération Française de Cancerologie Digestive, and UNICANCER.
Basile D, et al. Among authors: broudin c.
Ann Oncol. 2022 Jun;33(6):628-637. doi: 10.1016/j.annonc.2022.03.002. Epub 2022 Mar 16.
Ann Oncol. 2022.
PMID: 35306156
Free article.
Clinical Trial.